Acute Retention of Urine and Hypogonadism in a Man

Cox, R.; Stephenson, B. M.; Griffiths, David F.

doi:10.1016/s0022-5347(17)39171-1

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He further commented that no cases of prostate cancer had been reported among ‘eunuchs or eunuchoids’ (Moore, 1944). Nevertheless there were prior reports of BPH among men with long‐standing androgen deficiency (Deming et al ., 1935; Kretschmer, 1935; Deming & Neumann, 1939) subsequently confirmed by examples of BPH (Cox et al ., 1989; Scott, 1953; Yokoyama et al ., 1989) and prostate cancer (Sharkey & Fisher, 1960; Boccon‐Gibod et al ., 1991; Pienkos & Meissner, 1991; Uno et al ., 1998) among men with long‐standing severe androgen deficiency. Nevertheless, such cases seem exceptional and the prevalence of prostate disease among men with androgen deficiency appears to be low.…”

Section: Discussionmentioning

confidence: 99%

Effects of androgen deficiency and replacement on prostate zonal volumes

Jin

Conway

Handelsman

2001

Clinical Endocrinology

View full text Add to dashboard Cite

We conclude that, during mid-life, chronic androgen deficiency due to hypogonadism is associated with reduced central, peripheral and total prostate volumes. Reduced prostate volumes persist even during long-term maintenance of effective androgen replacement therapy with physiological testosterone concentrations until the fourth decade of life. After that, prostate volumes increase with age regardless of androgen deficiency or replacement. These findings suggest that, during mid-life, age is a more important determinant of prostate growth than ambient testosterone concentrations maintained in the physiological range. The persistently subnormal prostate volumes despite adequate androgen replacement therapy may explain the apparent paucity of cases of overt prostate disease among testosterone-treated androgen deficient men who retain protection against prostate disease despite physiological androgen replacement therapy.

show abstract